Searching journal content for breast cancer growth (as phrase) in full text.

Displaying results 1-10 of 80
For checked items
  1. Commentary:
    • Giorgio Secreto,
    • Paola Muti,
    • Milena Sant,
    • Elisabetta Meneghini,
    • and Vittorio Krogh
    Medical ovariectomy in menopausal breast cancer patients with high testosterone levels: a further step toward tailored therapy Endocr Relat Cancer 24 (11) C21-C29, doi:10.1530/ERC-17-0251 first published on 16 August 2017
    ...hormonal control for some time; however, the proliferative effect of estrogens ultimately prevails if the source of excessive androgen production is not removed (Fig.2). In addition to increased conversion into estrogens, androgen excess can stimulate breast cancer growth by both a direct bind to AR ~~~
  2. Research:
    • Gadi Shlomai,
    • Zara Zelenko,
    • Irini Markella Antoniou,
    • Marilyn Stasinopoulos,
    • Aviva Tobin-Hess,
    • Michael P Vitek,
    • Derek LeRoith,
    • and Emily Jane Gallagher
    OP449 inhibits breast cancer growth without adverse metabolic effects Endocr Relat Cancer 24 (10) 519-529, doi:10.1530/ERC-17-0077
    ...of insulin receptor signaling is associated with glycemic dysregulation. SET is a direct modulator of PP2A, which negatively regulates the PI3K/AKT/mTOR pathway. OP449, a SET inhibitor, decreases AKT/mTOR activation. Theeffects of OP449 treatment on breast cancer growth in the setting of pre ~~~
  3. Research:
    • Siker Kimbung,
    • Ching-yi Chang,
    • Pär-Ola Bendahl,
    • Laura Dubois,
    • J Will Thompson,
    • Donald P McDonnell,
    • and Signe Borgquist
    Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer Endocr Relat Cancer 24 (7) 339-349, doi:10.1530/ERC-16-0533 first published on 25 April 2017
    ...(ER) modulator capable of increasing breast cancer growth and metastasis. 27HC levels can be modulated by statins or direct inhibition of CYP27A1, thereby attenuating its pro-tumorigenic activities. Herein, the effect of statins on serum 27HC and tumor-specific CYP27A1 expression was evaluated in 42 ~~~
    OPEN ACCESS ARTICLE
  4. Research:
    • Alyson Murray,
    • Stephen F Madden,
    • Naoise C Synnott,
    • Rut Klinger,
    • Darran O'Connor,
    • Norma O'Donovan,
    • William Gallagher,
    • John Crown,
    • and Michael J Duffy
    Vitamin D receptor as a target for breast cancer therapy Endocr Relat Cancer 24 (4) 181-195, doi:10.1530/ERC-16-0463 first published on 17 February 2017
    ...breast cancer growth and invasion. Journal of Steroid Biochemistry and Molecular Biology 84 181–192. (doi:10.1016/ S0960-0760(03)00028-1) Friedrich M, Villena-Heinsen C, Tilgen W, Schmidt W, Reichrat J & Axt-Fliedner R 2002 Vitamin D receptor (VDR) expression is not a prognostic factor in breast can ~~~
  5. Editorial:
    • Wayne D Tilley
    Novel twists in hormone-mediated carcinogenesis Endocr Relat Cancer 23 (12) E9-E12, doi:10.1530/ERC-16-0466
    .... ( doi:10.1158/0008-5472.CAN-08-0594 ) Elizalde PV , Cordo Russo RI , Chervo MF & Schillaci R 2016 ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. Endocrine-Related Cancer 23 T243 T257 . ( doi:10.1530/ERC-16-0360 ) Hickey TE , Robinson JLL , Carroll JS ~~~
  6. Thematic Review:
    • Patricia V Elizalde,
    • Rosalía I Cordo Russo,
    • Maria F Chervo,
    • and Roxana Schillaci
    ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy Endocr Relat Cancer 23 (12) T243-T257, doi:10.1530/ERC-16-0360 first published on 7 October 2016
    ...(2016) 23, T243T257 2312 T243T257 Correspondence should be addressed to P V Elizalde Email patriciaelizalde@ibyme. conicet.gov.ar Key Words f nuclear ErbB-2 f breast cancer growth f metastasis f response to anti-ErbB-2 therapies f ErbB-2 transcriptional activity T244Thematic Review P V Elizalde et ~~~
  7. Thematic Review:
    • Elgene Lim,
    • Gerard Tarulli,
    • Neil Portman,
    • Theresa E Hickey,
    • Wayne D Tilley,
    • and Carlo Palmieri
    Pushing estrogen receptor around in breast cancer Endocr Relat Cancer 23 (12) T227-T241, doi:10.1530/ERC-16-0427 first published on 11 October 2016
    ...of AR that compromises receptor stability and potentially the response to androgenic ligands (Moore etal. 2012). This highlights a need to develop better models of apocrine breast cancer to fully understand the basis of AR-driven breast cancer growth in an ER-negative context. Currently ~~~
  8. Commentary:
    • Ioulia Chatzistamou and
    • Hippokratis Kiaris
    Modeling estrogen receptor-positive breast cancers in mice: is it the best we can do? Endocr Relat Cancer 23 (11) C9-C12, doi:10.1530/ERC-16-0397 first published on 12 September 2016
    ...supplementation for efficient breast cancer growth. Thus, while in pre-menopausal women 17-estradiol (E2) levels in the plasma reportedly exceed 27 pg/mL (Folkerd etal. 2014), in adult mice they are limited to levels below 13.7 pg/mL (Haisenleder etal. 2011). The presence of E2 at sufficient levels, above ~~~
  9. Research:
    • Srilatha Swami,
    • Aruna V Krishnan,
    • Jasmaine Williams,
    • Abhishek Aggarwal,
    • Megan A Albertelli,
    • Ronald L Horst,
    • Brian J Feldman,
    • and David Feldman
    Vitamin D mitigates the adverse effects of obesity on breast cancer in mice Endocr Relat Cancer 23 (4) 251-264, doi:10.1530/ERC-15-0557 first published on 27 January 2016
    ...to the interplay of local and systemic effects including elevated levels of leptin, circulating insulin, and IGF1 (Gilbert & Slingerland 2013). Leptin, a protein synthesized and secreted by adipose cells, circulates at levels proportional to adiposity and has many actions that stimulate breast cancer growth ~~~
  10. Review:
    • M Bullock
    FOXO factors and breast cancer: outfoxing endocrine resistance Endocr Relat Cancer 23 (2) R113-R130, doi:10.1530/ERC-15-0461 first published on 26 November 2015
    ...3KAKT pathway activation, a driver of breast cancer growth, causes down-regulation of FOXO tumor suppressor functions. This review will summarize what is currently known about the role of FOXOs in endocrine-resistance mechanisms. It will also suggest potential therapeutic strategies ~~~
For checked items

Search Results

Next 10 » New Search

Modify Results

Citation format:
Results / page:
Results order:

This search

  • Alert me when new articles matching this search are published
  • Download all citations on this page to my citation manager

New Articles: issue in progress

  1. December 2017, 24 (12)
  1. Current Issue
  1. Alert me to new issues of Endocrine-Related Cancer

Most